查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990425

异位性皮肤炎市场：2026-2032年全球市场预测（依产品、给药途径、严重程度、病患细分及分销管道划分）

Atopic Dermatitis Market by Product, Mode Of Administration, Severity Level, Patient Demographics, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，异位性皮肤炎市场价值将达到 220.2 亿美元，到 2026 年将成长至 233 亿美元，到 2032 年将达到 334.4 亿美元，复合年增长率为 6.14%。

主要市场统计数据
基准年 2025 220.2亿美元
预计年份：2026年 233亿美元
预测年份 2032 334.4亿美元
复合年增长率 (%) 6.14%

简要概述了正在重塑所有相关人员对异位性皮肤炎管理方式的临床、治疗和服务层面的趋势。

异位性皮肤炎的治疗模式正从主要以对症治疗为主，逐渐转向以治疗创新、整合式诊疗路径和以病人为中心的医疗服务模式为重点。本执行摘要概述了影响临床实践、产品开发和分销策略的核心趋势，重点关注这些趋势与生物製药、小分子疗法、医疗设备干预措施以及数位医疗在疾病长期管理中日益重要的作用之间的相互作用。

标靶治疗、数位化照护模式以及循证支付决策的创新如何重新定义异位性皮肤炎的治疗路径。

近年来，治疗方法、给药系统和医疗保健系统组织的同步创新带来了变革性变化，正在重塑人们对异位性皮肤炎治疗的预期。精准标靶生物製剂和JAK抑制剂为长期使用的外用药物提供了替代方案，重新定义了治疗流程。同时，照光治疗的进步和照光治疗通讯协定的改进，重新激发了人们对针对特定患者群体的医疗设备主导干预的兴趣。

该评估旨在评估近期关税趋势如何重塑整个异位性皮肤炎生态系统的筹资策略、供应链韧性和采购重点。

到2025年，近期实施的一系列关税政策的累积影响，为异位性皮肤炎相关相关人员的供应链规划、采购和成本管理带来了新的复杂性。关税调整影响了进口的药品活性成分、专用医疗设备组件和某些成品，促使製造商重新评估筹资策略，并考虑将生产外包到附近地区以及实现供应商网路多元化，以降低贸易政策波动带来的风险。

基于详细细分的洞察揭示了产品分类、给药途径、严重程度、患者人口统计特征和分销管道如何对治疗方法的采用和获取产生重大影响。

深入的市场细分阐明了治疗方法选择、给药方法、疾病严重程度、患者年龄层和分销管道如何相互交织并影响临床和商业性结果。从产品角度来看，此领域可分为两大类：「照光治疗」和「药物治疗」。照光治疗包括准分子雷射疗法、PUVA疗法和UVB疗法，每种疗法都有独特的疗效和操作特点，适用于特定的病变类型和医疗环境。药物治疗涵盖范围广泛，从传统的抗生素、抗病毒药物和抗真菌药物、抗组织胺和皮质类固醇，到新型药物，例如Janus激酶抑製剂和单株抗体，以及局部免疫调节剂，如Pimecrolimus和Tacrolimus。这些产品差异导致了处方实践的多样化，以及保险公司和临床医生对证据的不同要求。

区域医疗保健系统、监管环境和支付方做法如何造成全球市场治疗方法引入路径的差异。

区域趋势对临床实践、法律规范和商业策略有显着影响，需要从地缘政治和医疗保健系统的角度进行分析。在美洲，成熟的专科医疗网络、竞争激烈的生物製药市场以及完善的支付系统，促使人们更加关注疗效比较证据和患者准入项目。这些趋势为价格谈判和上市前核准流程带来了压力，同时也要求对产品差异化优势和可靠的长期安全性数据进行评估。

竞争格局概述，展示了製药创新者、医疗设备製造商和数位健康领域的新参与企业如何重塑商业化和伙伴关係模式。

异位性皮肤炎领域的竞争动态由多家实力雄厚的厂商共同塑造，包括成熟的製药公司、皮肤科专科诊所、早期生物技术创新企业、医疗设备製造商以及新兴的数位疗法提供者。大型製药公司持续投资于现有药物的生命週期管理，同时透过后期临床试验计画推动下一代生物製剂和口服小分子药物的研发。同时，规模较小的生技公司则致力于作用机制和特定适应症的创新，并经常与大型企业合作，以扩大生产和分销规模。

为了促进永续采用，需要采取实际有效的策略行动，协调临床证据、市场进入管道和业务永续营运。

产业领导者应优先考虑整合临床开发、市场准入和真实世界数据（REW）产生的整合策略。在商业化生命週期的早期阶段投资于可操作的临床试验和纵向安全性研究，将有助于与支付者进行谈判，并促进相关成果被纳入临床指南。同样，建立由支付方、临床医生和患者代表组成的多方相关人员咨询委员会，可以简化证据要求，并加快推广进程。

结合文献整合、相关人员访谈和跨細項分析的稳健调查方法，确保了透明且可重复的见解。

本报告的研究整合了公开的科学文献、监管申报文件、临床试验註册资讯以及对临床医生、支付方和行业高管的定性访谈。研究采用数据三角验证法来检验主题见解，并结合同行评审研究、专科临床指南和医疗系统采购报告中的证据，建构了关于治疗方法采纳和获取趋势的多方面观点。

对策略挑战进行简洁整合，强调整合临床证据、营运韧性和以患者为中心的服务，以最大限度地提高治疗效果。

总之，异位性皮肤炎的治疗正处于一个转折点，治疗方法创新、医疗服务模式的演变以及政策环境的变化交织在一起，既带来了机会，也带来了挑战。新的治疗方法和辅助技术有望显着改善患者的治疗效果，但相关人员必须应对复杂的报销流程、供应链的不确定性以及各地不同的要求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 异位性皮肤炎市场：依产品划分

  • 照光治疗
    • 准分子雷射疗法
    • PUVA疗法
    • UVB疗法
  • 药物治疗
    • 抗生素、抗病毒药物或抗真菌药物
    • 抗组织胺药
    • 皮质类固醇
    • Janus激酶（JAK）抑制剂
    • 单株抗体
    • Pimecrolimus或Tacrolimus

第九章：依给药途径分類的异位性皮肤炎市场

  • 口服
    • 胶囊
    • 药片
  • 肠外给药
    • 肌肉内部
    • 静脉
  • 外用
    • 奶油
    • 洗剂
    • 软膏

第十章：以严重程度分類的异位性皮肤炎市场

  • 轻度异位性皮肤炎
  • 中度异位性皮肤炎
  • 重度异位性皮肤炎

第十一章 依患者细分分類的异位性皮肤炎市场

  • 成年患者
  • 儿童患者

第十二章 异位性皮肤炎市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 异位性皮肤炎市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 异位性皮肤炎市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 异位性皮肤炎市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国异位性皮肤炎市场

第十七章：中国特异性皮肤炎市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Daavlin Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galderma Holding SA
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Johnson & Johnson Services Inc.
  • LEO Pharma A/S
  • Maruho Co., Ltd
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi SA
  • Solarc Systems Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-FE70EC183B6D

The Atopic Dermatitis Market was valued at USD 22.02 billion in 2025 and is projected to grow to USD 23.30 billion in 2026, with a CAGR of 6.14%, reaching USD 33.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.02 billion
Estimated Year [2026] USD 23.30 billion
Forecast Year [2032] USD 33.44 billion
CAGR (%) 6.14%

A concise orientation to the evolving clinical, therapeutic, and service-level dynamics reshaping atopic dermatitis management across stakeholders

Atopic dermatitis continues to evolve from a primarily symptom-managed condition to a focal point for therapeutic innovation, integrated care pathways, and patient-centered service models. This executive summary introduces the core dynamics shaping clinical practice, product development, and distribution strategies, emphasizing the interplay between biologic and small-molecule therapeutics, device-based interventions, and the rising role of digital health in long-term disease management.

The introduction sets the stage by highlighting how clinical heterogeneity and patient demographics drive differentiated care needs. It explains the rationale for examining discrete therapy classes and delivery modes alongside severity tiers and distribution mechanisms to provide a holistic perspective. By framing the topic in terms of unmet clinical needs, reimbursement complexity, and evolving provider behavior, this section establishes the analytical lens used across the report and primes readers for detailed insights on market structure, stakeholder incentives, and adoption barriers.

How innovations in targeted therapies, digital care models, and evidence-driven payer decision-making are redefining atopic dermatitis treatment pathways

Recent years have witnessed transformative shifts that are recalibrating expectations for atopic dermatitis care, with innovation occurring concurrently across therapeutics, delivery systems, and health system organization. Precision-targeting biologics and JAK inhibitors have reframed treatment algorithms by offering alternatives to long-established topical agents, while advances in light-based therapies and refinement of phototherapy protocols have renewed interest in device-led interventions for particular patient segments.

Alongside therapeutic innovation, care delivery is being reshaped by greater emphasis on patient experience and chronic disease management. Telehealth and remote monitoring platforms have matured, enabling sustained adherence support and symptom tracking that influence therapy selection and escalation patterns. In parallel, health economics evidence is becoming central to payer decision-making; comparative effectiveness and real-world safety data are increasingly used to negotiate formularies and reimbursement criteria.

Moreover, cross-sector collaboration is accelerating translational pathways: partnerships among academic dermatology centers, biotech firms developing targeted agents, and medical device manufacturers are shortening time-to-clinic for combination approaches. Finally, heightened regulatory scrutiny on long-term safety and post-market surveillance has raised the bar for lifecycle strategies, prompting manufacturers to integrate evidence generation plans into early commercial preparations. These converging shifts necessitate adaptive strategies from clinicians, payers, and commercial teams alike.

Assessing how recent tariff developments have reshaped sourcing strategies, supply-chain resilience, and procurement priorities across the atopic dermatitis ecosystem

The cumulative impact of recent tariff policies enacted through 2025 has introduced new layers of complexity into supply chain planning, procurement, and cost management for stakeholders involved in atopic dermatitis products. Tariff adjustments have affected imported active pharmaceutical ingredients, specialized device components, and certain finished goods, which has encouraged manufacturers to reassess sourcing strategies and to explore nearshoring or diversified vendor networks to mitigate exposure to trade policy volatility.

As a consequence, manufacturers are increasingly prioritizing supply-chain resilience by negotiating longer-term contracts with strategic suppliers, qualifying multiple component sources, and investing in regional manufacturing capabilities where feasible. These measures are complemented by enhanced customs compliance functions and scenario planning that stress-test commercial and clinical timelines. For healthcare providers and payers, tariff-driven cost pressures have reinforced the importance of value-based procurement and therapeutic substitution policies that favor treatments with robust long-term outcomes data.

In addition, the tariff environment has catalyzed conversations about domestic capacity-building, particularly for high-value biologics and complex device assemblies. Stakeholders are weighing the trade-offs between near-term cost increases and the strategic benefits of reduced import dependency, faster replenishment cycles, and improved regulatory alignment. Ultimately, the policy backdrop underscores the necessity for integrated commercial and operational strategies that account for trade-related risks alongside clinical and market-access considerations.

Deep segmentation-driven insights that illuminate how product classes, administration routes, severity tiers, demographics, and channels materially affect treatment adoption and access

Insightful segmentation of the market clarifies how therapeutic choices, administration modalities, disease severity, patient age groups, and distribution channels intersect to shape clinical and commercial outcomes. When viewed through the product lens, the landscape is characterized by two broad categories: light therapy and medication. Light therapy encompasses excimer laser therapy, PUVA therapy, and UVB therapy, each offering distinct efficacy and operational profiles suitable for particular lesion patterns and care settings. Medication spans a range from conventional antibiotics, antivirals or antifungals, antihistamines, and corticosteroids to newer classes such as Janus kinase inhibitors and monoclonal antibodies, as well as topical immunomodulators like pimecrolimus or tacrolimus. These product distinctions drive heterogeneous prescribing practices and different evidence requirements for payers and clinicians.

Examining mode of administration reveals further granularity. Oral administration, including capsules and tablets, typically supports systemic management and is favored in more extensive disease or when topical adherence is poor. Parenteral administration, divided into intramuscular and intravenous routes, is associated with specialty clinic delivery, higher monitoring requirements, and different reimbursement pathways. Topical administration, delivered as creams, lotions, or ointments, remains central for maintenance therapy and for patients with localized disease, balancing tolerability with the need for sustained adherence and patient education.

Stratifying by severity level-mild, moderate, and severe-provides practical guidance for treatment sequencing and resource allocation. Mild disease often responds to topical therapies and basic self-management, while moderate cases may require escalation to systemic agents or phototherapy. Severe atopic dermatitis frequently necessitates specialty care, combination therapy approaches, and more intensive monitoring, which influences payer review processes and clinical referral patterns. Patient demographics also critically shape clinical pathways: adult patients often present with distinct comorbidity profiles and long-term treatment histories compared with pediatric patients, whose developmental considerations and caregiver dynamics inform adherence strategies and safety monitoring.

Distribution channel segmentation-hospital pharmacies, online pharmacies, and retail pharmacies-further determines access dynamics, formulary placement, and patient support program design. Hospital pharmacies and specialty infusion centers are pivotal for injectable biologics and intravenous therapies, while online pharmacies are increasingly important for chronic oral and topical therapies due to convenience and subscription models. Retail pharmacies remain fundamental for last-mile distribution and patient counseling, particularly for topical agents and over-the-counter adjuncts. Integrating these segmentation dimensions enables stakeholders to tailor clinical development, market-access tactics, and patient-support services to the nuanced needs of different subpopulations.

How regional healthcare systems, regulatory landscapes, and payer approaches are creating differentiated pathways for therapy adoption across global markets

Regional dynamics significantly influence clinical practice, regulatory frameworks, and commercial strategies, and must be analyzed through a geopolitical and health-system lens. In the Americas, established specialty care networks, a competitive biologics market, and sophisticated payer systems drive a focus on comparative effectiveness evidence and patient access programs. These dynamics reward clear differentiation and robust long-term safety data while also creating pressures around pricing negotiations and prior authorization processes.

Across Europe, Middle East & Africa, heterogeneity is pronounced: Western European markets tend to have mature HTA processes and well-defined reimbursement pathways that emphasize cost-effectiveness, while some Middle Eastern and African markets are working to expand specialty care infrastructure and access to advanced therapies. This region therefore necessitates adaptable market-access strategies that address variable procurement mechanisms and local capacity constraints. Importantly, real-world evidence and local pharmacoeconomic modeling are often decisive in securing access across diverse healthcare finance environments in this region.

In the Asia-Pacific region, growing healthcare investment, expanding dermatology specialty networks, and increasing patient awareness are accelerating uptake of innovative therapies, although market entry strategies must account for varying regulatory timelines and price sensitivity. Local manufacturing partnerships and tailored patient support initiatives can be effective in addressing affordability and distribution challenges. Across regions, cross-border collaboration on regulatory science and post-market surveillance is becoming more salient, and companies that can align regional evidence-generation plans with local stakeholder expectations are positioned to achieve more consistent adoption trajectories.

Competitive landscape overview showing how pharmaceutical innovators, device manufacturers, and digital health entrants are reshaping commercialization and partnership models

Competitive dynamics in atopic dermatitis are shaped by a mix of established pharmaceutical firms, specialty dermatology companies, early-stage biotech innovators, medical device manufacturers, and emerging digital therapeutics providers. Leading pharmaceutical players continue to invest in lifecycle management for established classes while simultaneously advancing next-generation biologics and oral small molecules through late-stage clinical programs. Meanwhile, smaller biotech firms contribute innovation in mechanism of action and niche indications, often partnering with larger organizations to scale manufacturing and distribution.

Device manufacturers are enhancing phototherapy platforms and developing outpatient-friendly delivery systems that expand access beyond tertiary centers. These product innovations are frequently supported by evidence-generation strategies that demonstrate comparative effectiveness, ease of use, and integration into clinic workflows. Digital health vendors and startups are complementing pharmacologic and device-based care with adherence tools, teledermatology services, and symptom-tracking platforms that increase sustained engagement and provide real-world data to support value claims.

Across the competitive landscape, companies that combine robust clinical data packages with agile market-access approaches and strong patient support ecosystems are most successful at securing durable uptake. Strategic partnerships, licensing agreements, and value-based contracting are increasingly common as firms seek to mitigate access barriers and align incentives with payers and providers. Overall, the market rewards a balance of scientific differentiation, operational excellence, and stakeholder-centric commercialization models.

Practical, high-impact strategic actions for leaders to align clinical evidence, market-access pathways, and operational resilience to drive sustainable adoption

Industry leaders should prioritize integrated strategies that align clinical development with market-access and real-world evidence generation. Investing in pragmatic trials and longitudinal safety studies early in the commercial lifecycle will support payer negotiations and clinical guideline inclusion. Similarly, establishing multi-stakeholder advisory boards that include payers, clinicians, and patient representatives can streamline evidence requirements and accelerate adoption pathways.

Operationally, building supply-chain redundancy and regional manufacturing options will reduce exposure to trade policy shocks and support faster time-to-market. Commercial teams should design tailored patient-support programs that reflect the needs of adult and pediatric populations, and leverage digital adherence tools to improve long-term outcomes. Finally, pursue flexible pricing and contracting mechanisms such as outcomes-based agreements where appropriate, and design value communication that speaks to both clinical endpoints and broader health system impacts, including resource utilization and patient quality of life.

Robust methodological approach combining literature synthesis, stakeholder interviews, and cross-segmentation analysis to ensure transparent, reproducible insights

The research underlying this report synthesizes publicly available scientific literature, regulatory filings, clinical trial registries, and primary qualitative interviews with clinicians, payers, and industry executives. Data triangulation was applied to validate thematic findings, combining evidence from peer-reviewed studies, specialty clinical guidelines, and health-system procurement reports to create a multi-dimensional view of therapeutic adoption and access dynamics.

Analytical methods included cross-segmentation mapping to identify interaction effects between product classes, modes of administration, severity levels, patient demographics, and distribution channels. Regional analysis drew on country-specific regulatory documents and payer guidance to contextualize adoption barriers. Qualitative insights were derived from semi-structured interviews designed to capture decision criteria used by clinicians and payers, while attention was paid to ensuring confidentiality and representativeness across stakeholder types. Throughout, the methodology emphasized transparency, reproducibility, and the integration of both clinical and commercial perspectives.

A concise synthesis of strategic imperatives emphasizing the integration of clinical evidence, operational resilience, and patient-centric access to maximize therapeutic impact

In conclusion, atopic dermatitis management stands at an inflection point where therapeutic innovation, evolving care delivery models, and shifting policy environments converge to create both opportunities and challenges. The emergent therapies and supportive technologies offer the potential to substantially improve patient outcomes, yet stakeholders must navigate complex reimbursement pathways, supply-chain uncertainties, and diverse regional requirements.

Successful organizations will be those that align scientific development with pragmatic evidence generation, invest in resilient operational models, and design patient-centric access programs. By integrating clinical, commercial, and policy considerations into a coherent strategy, decision-makers can better position their organizations to deliver meaningful improvements in care while maintaining sustainable business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Atopic Dermatitis Market, by Product

  • 8.1. Light Therapy
    • 8.1.1. Excimer Laser Therapy
    • 8.1.2. PUVA Therapy
    • 8.1.3. UVB Therapy
  • 8.2. Medication
    • 8.2.1. Antibiotics, Antivirals or Antifungals
    • 8.2.2. Antihistamines
    • 8.2.3. Corticosteroid
    • 8.2.4. Janus Kinase (JAK) Inhibitors
    • 8.2.5. Monoclonal Antibodies
    • 8.2.6. Pimecrolimus or Tacrolimus

9. Atopic Dermatitis Market, by Mode Of Administration

  • 9.1. Oral Administration
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Parenteral Administration
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Topical Administration
    • 9.3.1. Cream
    • 9.3.2. Lotion
    • 9.3.3. Ointment

10. Atopic Dermatitis Market, by Severity Level

  • 10.1. Mild Atopic Dermatitis
  • 10.2. Moderate Atopic Dermatitis
  • 10.3. Severe Atopic Dermatitis

11. Atopic Dermatitis Market, by Patient Demographics

  • 11.1. Adult Patients
  • 11.2. Pediatric Patients

12. Atopic Dermatitis Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Atopic Dermatitis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Atopic Dermatitis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Atopic Dermatitis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Atopic Dermatitis Market

17. China Atopic Dermatitis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bausch Health Companies Inc.
  • 18.9. Biofrontera AG
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Chugai Pharmaceutical Co., Ltd.
  • 18.12. Daavlin Company
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. Galderma Holding SA
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Incyte Corporation
  • 18.18. Johnson & Johnson Services Inc.
  • 18.19. LEO Pharma A/S
  • 18.20. Maruho Co., Ltd
  • 18.21. Novartis AG
  • 18.22. Perrigo Company PLC
  • 18.23. Pfizer, Inc.
  • 18.24. Regeneron Pharmaceuticals, Inc
  • 18.25. Sanofi SA
  • 18.26. Solarc Systems Inc.
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. UCB S.A.
  • 18.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)